US · BIAFW
bioAffinity Technologies, Inc.
Price · as of 2026-10-18
$0.32
Market cap 2.49M
Price history
The price history chart is shown only to users with a Pro subscription.
InvestorsCraft valuation
Fair value (AI, DCF / IC, Graham) for bioAffinity Technologies, Inc. (BIAFW) is available to Pro members and via the machine API.
- AI valuation — available
- Intrinsic / IC value — available
- Upside vs price — available
Valuation history
Annual price overlaid with each model's fair value. Y-axis is log scale.
The valuation history chart is shown only to users with a Pro subscription.
Historic valuation ratios
Pick a category, then toggle metrics to compare.
Historic valuation ratios are shown only to users with a Pro subscription.
Line items
Line items
Line items
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.
- CEO
- Maria Zannes
- Employees
- 57
- Beta
- -1.05
The peer comparison table is shown only to users with a Pro subscription.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice.